{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T06:31:23Z","timestamp":1769841083282,"version":"3.49.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,6,17]],"date-time":"2014-06-17T00:00:00Z","timestamp":1402963200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1007\/s00280-014-2485-x","type":"journal-article","created":{"date-parts":[[2014,6,19]],"date-time":"2014-06-19T11:54:08Z","timestamp":1403178848000},"page":"349-357","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Third-space fluid distribution of pemetrexed in non-small cell lung cancer patients"],"prefix":"10.1007","volume":"74","author":[{"given":"Per Hartvig","family":"Honor\u00e9","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sigrid J\u00f3hansd\u00f3ttir","family":"Joensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steen Honor\u00e9","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"Mellemgaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,6,17]]},"reference":[{"key":"2485_CR1","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1056\/NEJM197504172921607","volume":"292","author":"E Frei III","year":"1975","unstructured":"Frei E III, Jaffe N, Tattersall MH, Pitman S, Parker L (1975) New approaches to cancer chemotherapy with methotrexate. New Engl J Med 292:846","journal-title":"New Engl J Med"},{"issue":"1","key":"2485_CR2","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/cpt197823168","volume":"23","author":"WE Evans","year":"1978","unstructured":"Evans WE, Pratt CB (1978) Effect of pleural effusion on high-dose methotrexate kinetics. Clin Pharmacol Ther 23(1):68\u201372","journal-title":"Clin Pharmacol Ther"},{"key":"2485_CR3","isbn-type":"print","doi-asserted-by":"crossref","DOI":"10.1002\/9781444312829","volume-title":"Lung function: physiology, measurement and application in medicine, Chapter 1 and 2","author":"JE Cotes","year":"2006","unstructured":"Cotes JE (2006) Lung function: physiology, measurement and application in medicine, Chapter 1 and 2, 6th edn. Blackwell publishing, Australia. ISBN 978-0-632-06493-9","ISBN":"https:\/\/id.crossref.org\/isbn\/9780632064939","edition":"6"},{"key":"2485_CR4","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ccm.2013.05.004","volume":"34","author":"JT Thomas","year":"2013","unstructured":"Thomas JT, Musani AI (2013) Malignant pleural effusions: a review. Clin Chest Med 34:459\u2013471","journal-title":"Clin Chest Med"},{"issue":"1","key":"2485_CR5","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1055\/s-0031-1273942","volume":"28","author":"Y Hyeon","year":"2011","unstructured":"Hyeon Y (2011) Management of pleural effusion, empyema and lung abscess. Semin Intervent Radiol 28(1):75\u201386","journal-title":"Semin Intervent Radiol"},{"key":"2485_CR6","doi-asserted-by":"crossref","DOI":"10.1201\/b13502","volume-title":"Textbook of pleural diseases","author":"R Light","year":"2008","unstructured":"Light R, Lee GY (2008) Textbook of pleural diseases, 2nd edn. Hodder Education, London","edition":"2"},{"key":"2485_CR7","isbn-type":"print","volume-title":"Principles and practice of lung cancer","author":"HI Pass","year":"2010","unstructured":"Pass HI, Carbone DP, Johnson DH, Minna JD et al (2010) Principles and practice of lung cancer, 4th edn. Lippincott Williams & Wilkins, USA. ISBN 978-0-7817-7365-2","ISBN":"https:\/\/id.crossref.org\/isbn\/9780781773652","edition":"4"},{"issue":"54","key":"2485_CR8","first-page":"S413","volume":"5","author":"K Zarogoulidis","year":"2013","unstructured":"Zarogoulidis K, Zarogoulidis P, Darwiche K, Tsakiridis K et al (2013) Malignant pleural effusion and algorithm management. J Thorac Dis 5(54):S413\u2013S419","journal-title":"J Thorac Dis"},{"key":"2485_CR9","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/S0039-6109(02)00036-1","volume":"82","author":"JB Putnam","year":"2002","unstructured":"Putnam JB (2002) Malignant pleural effusions. Surg Clin North Am 82:867\u2013883","journal-title":"Surg Clin North Am"},{"key":"2485_CR10","first-page":"2605","volume":"9","author":"TL Hung","year":"2003","unstructured":"Hung TL, Chen FF, Liu JM, Lai WW et al (2003) Clinical evaluation of HER-2\/neu protein in malignant pleural effusion-associated lung adenocarcinoma and as tumor marker in pleural effusion diagnosis. Clin Cancer Res 9:2605\u20132612","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2485_CR11","doi-asserted-by":"crossref","first-page":"760","DOI":"10.47102\/annals-acadmedsg.V37N9p760","volume":"37","author":"TE Gonlugur","year":"2008","unstructured":"Gonlugur TE, Gonlugur U (2008) Transudates in malignancy: still a role for pleural fluid. Ann Acad Med Singapore 37(9):760\u2013763","journal-title":"Ann Acad Med Singapore"},{"key":"2485_CR12","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.thorsurg.2012.10.004","volume":"23","author":"R Thomas","year":"2013","unstructured":"Thomas R, Lee G (2013) Causes and management of common benign pleural effusions. Thorac Surg Clin 23:25\u201342","journal-title":"Thorac Surg Clin"},{"key":"2485_CR13","first-page":"2639","volume":"163","author":"PS Clementsen","year":"2001","unstructured":"Clementsen PS (2001) Pleuracentese. Ugeskr L\u00e6ger 163:2639\u20132640","journal-title":"Ugeskr L\u00e6ger"},{"key":"2485_CR14","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1183\/09031936.97.10081701","volume":"10","author":"RW Light","year":"1997","unstructured":"Light RW, Hamm H (1997) Malignant pleural effusion: would the real cause please stand up? Eur Respir J 10:1701\u20131702","journal-title":"Eur Respir J"},{"key":"2485_CR15","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/jso.22100","volume":"105","author":"JT Kaifi","year":"2012","unstructured":"Kaifi JT, Toth JW, Gusani NJ, Kimichi ET et al (2012) Multidisciplinary management of malignant pleural effusion. J Surg Oncol 105:731\u2013738","journal-title":"J Surg Oncol"},{"issue":"11","key":"2485_CR16","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1200\/JCO.1995.13.11.2842","volume":"13","author":"DA Rinaldi","year":"1995","unstructured":"Rinaldi DA, Burris HA, Dorr FA, Woodworth JG et al (1995) Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation. J Clin Oncol 13(11):2842\u20132850","journal-title":"J Clin Oncol"},{"key":"2485_CR17","unstructured":"Guidance for Industry\u2014Bioanalytical Method Validation (2010) U S Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research 2001. pp 1\u201322"},{"issue":"7521","key":"2485_CR18","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1136\/bmj.331.7521.903","volume":"331","author":"D Altman","year":"2005","unstructured":"Altman D, Bland MJ (2005) Standard deviations and standard errors. Statistics note. BMJ 331(7521):903","journal-title":"BMJ"},{"key":"2485_CR19","isbn-type":"print","volume-title":"Basic pharmacokinetic and pharmacodynamic: an integrated textbook and computer simulations","author":"SE Rosenbaum","year":"2011","unstructured":"Rosenbaum SE (2011) Basic pharmacokinetic and pharmacodynamic: an integrated textbook and computer simulations. Wiley, New Jersey. ISBN 978-0-470-56906-1","ISBN":"https:\/\/id.crossref.org\/isbn\/9780470569061"},{"key":"2485_CR20","volume-title":"Clinical pharmacokinetics and pharmacodynamics: concepts and applications","author":"M Rowland","year":"2011","unstructured":"Rowland M, Tozer TN (2011) Clinical pharmacokinetics and pharmacodynamics: concepts and applications, 4th edn. Williams & Wilkins, Lippincott","edition":"4"},{"key":"2485_CR21","unstructured":"Guidance for Industry (1998) Pharmacokinetics in patients with impaired renal function\u2014study design, data analysis, and impact on dosing and labeling. http:\/\/www.fda.gov\/downloads\/Drugs\/Guidances\/UCM204959.pdf"},{"key":"2485_CR22","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s002800050992","volume":"44","author":"DA Rinaldi","year":"1999","unstructured":"Rinaldi DA, Kuhn JG, Burris HA, Dorr FA et al (1999) A phase I evaluation of multi-targeted antifolate (MTA, LY231514), administered every 21\u00a0days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother Pharmacol 44:372\u2013380","journal-title":"Cancer Chemother Pharmacol"},{"key":"2485_CR23","first-page":"605","volume":"4","author":"AC McDonald","year":"1998","unstructured":"McDonald AC, Vasey PA, Adams L et al (1998) A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate. Clin Cancer Res 4:605\u2013610","journal-title":"Clin Cancer Res"},{"key":"2485_CR24","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s002800000144","volume":"46","author":"D Quellet","year":"2000","unstructured":"Quellet D, Periclou AP, Johnson RD, Woodworth JR et al (2000) Population pharmacokinetics of pemetrexed disodium (ALIMTA) in patients with cancer. Cancer Chemother Pharmacol 46:227\u2013234","journal-title":"Cancer Chemother Pharmacol"},{"key":"2485_CR25","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1158\/1078-0432.CCR-08-0128","volume":"15","author":"NJ Dickgreber","year":"2009","unstructured":"Dickgreber NJ, Fink TH, Latz JE, Hossain AM et al (2009) Phase I and pharmacokinetic study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancer. Clin Cancer Res 15:382\u2013389","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2485_CR26","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1158\/1078-0432.CCR-09-3324","volume":"16","author":"NJ Dickgreber","year":"2010","unstructured":"Dickgreber NJ, Sorensen JB, Paz-Ares LG, Schytte TK et al (2010) Pemetrexed safety and pharmacokinetics in patients with third-space fluid. Clin Cancer Res 16(10):2872\u20132880","journal-title":"Clin Cancer Res"},{"key":"2485_CR27","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/sj.bjc.6603321","volume":"95","author":"K Nakagawa","year":"2006","unstructured":"Nakagawa K, Kudoh S, Matsui K, Negoro S et al (2006) A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours. Br J Cancer 95:677\u2013682","journal-title":"Br J Cancer"},{"key":"2485_CR28","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00280-005-0036-1","volume":"57","author":"JE Latz","year":"2006","unstructured":"Latz JE, Chaudhary A, Ghosh A, Johnson RD (2006) Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients. Cancer Chemother Pharmacol 57:401\u2013411","journal-title":"Cancer Chemother Pharmacol"},{"issue":"16","key":"2485_CR29","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1200\/JCO.2002.10.073","volume":"20","author":"A Hughes","year":"2002","unstructured":"Hughes A, Calvert P, Azzabi A, Plummer R et al (2002) Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. J Clin Oncol 20(16):3533\u20133544","journal-title":"J Clin Oncol"},{"key":"2485_CR30","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00280-002-0512-9","volume":"50","author":"J Li","year":"2002","unstructured":"Li J, Gwilt P (2002) The effect of malignant effusions on methotrexate disposition. Cancer Chemother Pharmacol 50:373\u2013382","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"2485_CR31","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1200\/JCO.2004.00.9720","volume":"24","author":"AC Mita","year":"2006","unstructured":"Mita AC, Sweeney CJ, Baker SD, Goetz A et al (2006) Phase I and pharmacokinetic study of pemetrexed administered every 3\u00a0weeks to advanced cancer patients with normal and impaired renal function. J Clin Oncol 24(4):552\u2013562","journal-title":"J Clin Oncol"},{"key":"2485_CR32","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nrc1629","volume":"5","author":"SD Undevia","year":"2005","unstructured":"Undevia SD, Gomez-Abuin G, Ratain MJ (2005) Pharmacokinetic variability of anticancer agents. Nat Rev Cancer 5:447\u2013458","journal-title":"Nat Rev Cancer"},{"key":"2485_CR33","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/cpt1973144part1572","volume":"14","author":"DH Huffman","year":"1973","unstructured":"Huffman DH (1973) Pharmacokinetics of methotrexate. Clin Pharmacol Ther 14:572\u2013579","journal-title":"Clin Pharmacol Ther"},{"key":"2485_CR34","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1172\/JCI107362","volume":"52","author":"BA Chabner","year":"1973","unstructured":"Chabner BA, Young RC (1973) Threshold methotrexate concentration for in vivo inhibition of DNA synthesis in normal and tumorous target tissues. J Clin Invest 52:1804\u20131811","journal-title":"J Clin Invest"},{"issue":"5","key":"2485_CR35","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1023\/A:1012299115260","volume":"28","author":"SL Beal","year":"2001","unstructured":"Beal SL (2001) Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 28(5):481\u2013504","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"2","key":"2485_CR36","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1208\/s12248-009-9112-5","volume":"11","author":"M Bergstrand","year":"2009","unstructured":"Bergstrand M, Karlsson MO (2009) Handling data below the limit of quantification in mixed effect models. AAPS J 11(2):371\u2013380","journal-title":"AAPS J"},{"key":"2485_CR37","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1023\/A:1021441407898","volume":"19","author":"V Duval","year":"2002","unstructured":"Duval V, Karlsson MO (2002) Impact of omission or replacement of data below the limit of quantification on parameter estimates in a two-compartment model. Pharm Res 19:1835\u20131840","journal-title":"Pharm Res"},{"key":"2485_CR38","unstructured":"Bonate PL (2011) Pharmacokinetic-pharmacodynamic modeling and simulation. Chapter 8. Nonlinear mixed effects models: practical issues, 2nd edn. Springer, Deerfield, pp 303\u2013358. doi: 10.1007\/978-1-4419-9485-1-8"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2485-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-014-2485-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2485-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T11:45:40Z","timestamp":1689335140000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-014-2485-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,17]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["2485"],"URL":"https:\/\/doi.org\/10.1007\/s00280-014-2485-x","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,17]]}}}